/cloudfront-us-east-1.images.arcpublishing.com/morningstar/OBA7UVI75RGFDOHGJTZ2FK542Q.jpg)
Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies.
Featured
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/JNGGL2QVKFA43PRVR44O6RYGEM.png)
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/RFJBWBYYTARXBNOTU6VL4VSE4Q.png)
Latest Company Reports
- CRONCronos Group Inc
Cronos Is Unlikely to Generate Positive Adjusted EBITDA for the Foreseeable Future
/s3.amazonaws.com/arc-authors/morningstar/220f0649-85f9-4004-a281-b91d9bc53139.jpg)
- Rating
- Price
- $2.34
- Fair Value
- $3.10
- Uncertainty
- Very High
- Economic Moat
- Kwmjs
- Capital Allocation
- Vwcjczxs
- CGCCanopy Growth Corp
US Deals Help Unlock Some Value but Doesn't Help Canopy Growth's Lagging Canadian Operations
- Rating
- Price
- $6.45
- Fair Value
- $8.50
- Uncertainty
- Extreme
- Economic Moat
- Bdrfq
- Capital Allocation
- Ntkvz
- WBAWalgreens Boots Alliance Inc
Walgreens' Recovery Looks Uncertain as Retail Continues to Suffer and More Store Closures Underway
/s3.amazonaws.com/arc-authors/morningstar/b76d1412-e5af-4b94-8222-8cb66fe23dbe.jpg)
- Rating
- Price
- $12.18
- Fair Value
- $21.00
- Uncertainty
- Very High
- Economic Moat
- Sbvl
- Capital Allocation
- Trws
- TLRYTilray Brands Inc
Tilray's Mixed Portfolio Unlikely to Yield Synergies as Canadian Market Remains a Major Challenge
- Rating
- Price
- $1.66
- Fair Value
- $6.00
- Uncertainty
- Very High
- Economic Moat
- Qwkk
- Capital Allocation
- Lmwtpwmb
- ACBAurora Cannabis Inc
Aurora's Debt Load Severely Reduced, but Its Small Size Will Hinder Investment Ability and Growth
- Rating
- Price
- $4.62
- Fair Value
- $2.50
- Uncertainty
- Extreme
- Economic Moat
- Kdgwb
- Capital Allocation
- Zrt
- ILMNIllumina Inc
Illumina Spins Off Grail to Shareholders
/s3.amazonaws.com/arc-authors/morningstar/27df33e4-c5eb-4dc8-805e-babc7c688b65.jpg)
- Rating
- Price
- $104.38
- Fair Value
- $566.00
- Uncertainty
- High
- Economic Moat
- Bcmfpg
- Capital Allocation
- Mfjhsfzsq
- ALNYAlnylam Pharmaceuticals Inc
Narrow-Moat Alnylam's Positive Data in Vutrisiran ATTR-CM Trial Should Drive Strong Long-Term Growth
/s3.amazonaws.com/arc-authors/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
- Rating
- Price
- $243.00
- Fair Value
- $788.00
- Uncertainty
- High
- Economic Moat
- Zswbnm
- Capital Allocation
- Gbxsgzlmv
- CURLFCuraleaf Holdings Inc
Curaleaf Positioned for Long-Term Growth From US and International Market Tailwinds
- Rating
- Price
- $3.85
- Fair Value
- $59.00
- Uncertainty
- Very High
- Economic Moat
- Bcbx
- Capital Allocation
- Lrxgnddtn
- GTBIFGreen Thumb Industries Inc
Green Thumb's Growth Should Benefit From Easing Federal Prohibition and New State Legalizations
- Rating
- Price
- $11.99
- Fair Value
- $21.00
- Uncertainty
- Very High
- Economic Moat
- Ksdp
- Capital Allocation
- Vzjkvqbpq
- LHLabcorp Holdings Inc
LabCorp Can Prioritize Diagnostics Now Without Distractions
/s3.amazonaws.com/arc-authors/morningstar/adf521c2-d9af-477d-a6bc-03ec7ca34c40.jpg)
- Rating
- Price
- $203.51
- Fair Value
- $172.35
- Uncertainty
- Medium
- Economic Moat
- Lwzkmxk
- Capital Allocation
- Cwyxjvdg
- QGENQiagen NV
Qiagen Still Pushing for Higher Growth Than Its End Markets
- Rating
- Price
- $41.09
- Fair Value
- $17.00
- Uncertainty
- Medium
- Economic Moat
- Qmvx
- Capital Allocation
- Tpwnbjntx
- TFXTeleflex Inc
Teleflex Is Expanding Its Portfolio of Surgical and Interventional Devices
/s3.amazonaws.com/arc-authors/morningstar/0f2146bc-8a38-4a78-8fb8-fe1b37fb7287.jpg)
- Rating
- Price
- $210.33
- Fair Value
- $421.00
- Uncertainty
- Medium
- Economic Moat
- Jxhw
- Capital Allocation
- Plw
- ATRAptarGroup Inc
Aptar's Profitability Improving Due to Pharma Growth and Cost Controls
- Rating
- Price
- $140.81
- Fair Value
- $922.00
- Uncertainty
- Medium
- Economic Moat
- Vdkbypv
- Capital Allocation
- Ywbnksqkc
- NVONovo Nordisk A/S ADR
Novo Nordisk's Cardiometabolic Innovation Supports a Wide Moat
/s3.amazonaws.com/arc-authors/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
- Rating
- Price
- $142.74
- Fair Value
- $26.00
- Uncertainty
- High
- Economic Moat
- Pcj
- Capital Allocation
- Zhzhrqbdrg
- BMRNBiomarin Pharmaceutical Inc
BioMarin's Rare Disease Portfolio, Led by Voxzogo, Supports a Narrow Moat
- Rating
- Price
- $82.33
- Fair Value
- $63.00
- Uncertainty
- High
- Economic Moat
- Cmxbkf
- Capital Allocation
- Tbfxzvh
Largest Stocks in the Healthcare Sector
|
1-Day Chart
|
Name
|
Industry
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Drug Manufacturers - General | Xrfklnynn | Zcf | $815.2 Bil | |||
| Novo Nordisk A/S ADR
NVO
| Biotechnology | Xzrvfwjtmb | Jmwxz | $642.9 Bil | |||
| UnitedHealth Group Inc
UNH
| Healthcare Plans | Gxjpdfwdm | Dzwbk | $468.7 Bil | |||
| Johnson & Johnson
JNJ
| Drug Manufacturers - General | Bjztntsv | Ptb | $351.8 Bil | |||
| Merck & Co Inc
MRK
| Drug Manufacturers - General | Ytwtqrwqq | Qjk | $313.6 Bil | |||
| AbbVie Inc
ABBV
| Drug Manufacturers - General | Kxwqqkhwn | Vzsxs | $302.9 Bil | |||
| AstraZeneca PLC ADR
AZN
| Drug Manufacturers - General | Cntnnzbw | Kjlpj | $242.2 Bil | |||
| Novartis AG ADR
NVS
| Drug Manufacturers - General | Zqwpbxs | Xxj | $218.3 Bil | |||
| Thermo Fisher Scientific Inc
TMO
| Diagnostics & Research | Tpjbykky | Wzjn | $211.1 Bil | |||
| Danaher Corp
DHR
| Diagnostics & Research | Kcrmxfht | Zgvvgk | $185.1 Bil |
More in Healthcare
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/KD4XZLC72BDERAS3VXD6QM5MUY.png)
Healthcare Stocks: Valuations Look Attractive Across Almost All Industries
Our top picks in the sector are Illumina, Moderna, and Zimmer Biomet.
Healthcare: Valuations Look Attractive Across Almost All Industries
We think the best healthcare stocks include Illumina, Moderna, and Zimmer Biomet.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/HDPMMDGUA5CUHI254MRUHYEFWU.png)
3 Gold-Rated Funds Whose Managers Love Healthcare Stocks
Although the sector has suffered recently, it won’t hurt these well-run funds forever.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/22DGCGOHMJC7HHQIF2CERYV4JM.png)
Healthcare: Valuations Look Attractive Across Most Industries
We view the sector as undervalued, as the market is not fully appreciating its innovations.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/7B2BNWABPGQEALZ7BNPW5JW3PM.jpg)
A Checklist for Open Enrollment Season
If you’re signing up for employer-provided benefits, don’t just re-up for last year’s choices.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/L644DYLVFJDCLOIAOSBZUGFIEU.png)
8 Undervalued Quality Healthcare Stocks
These wide-moat healthcare stocks are trading below their fair value estimates.
Healthcare Stock Outlook: Innovative Products and Defensive Nature Should Support Solid Results in Uncertain Times
We see plenty of opportunities in healthcare, especially in biopharma, healthcare providers, healthcare plans, and diagnostics and research.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/4TYZEEXD3RGWNKTVNUJBWDUFAM.jpg)
Is UnitedHealth Stock a Buy, Sell, or Fairly Valued After Earnings?
Here’s what we think of UnitedHealth stock as surging demand for healthcare could strain near-term margins.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/66O6YFGQPK4B3UEPMKAPFPKPOA.png)
2 Undervalued Medtech Stocks: Opportunities in Liquid Biopsy
Liquid biopsies could usher in a paradigm shift in cancer detection and grow exponentially.
Healthcare Sector Outlook: Defensive Attributes Should Shore Up Stocks Amid Economic Headwinds
Biopharma and drug firms’ core fundamentals should stay solid if challenges persist.